Telix Pharmaceuticals Limited

TLX.ASX

Health Care

Development and commercialising molecularly targeted radiation products for the treatment of cancer.

Market Data

Price

$14.910

+0.0%
Market Cap

$5.0B

P/E Ratio

-100000.0x

EPS

$-0.030

Div. Yield

0.00%

52-Week Change

-0.1%

Recent Announcements

3 Jul 2026 Sph Neutral

Ceasing to be a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.

30 Jun 2026 Sph Neutral

Becoming a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (6.5532%).

25 Jun 2026 Sph Neutral

Becoming a substantial holder

Vanguard Group (The Vanguard Group, Inc. became a substantial holder (5.217%).

23 Jun 2026 Sph Neutral

Ceasing to be a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.

26 May 2026 Sph Neutral

Becoming a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.9153%).

17 Apr 2026 Sph Neutral

Becoming a substantial holder from CGF

CGF became a substantial holder (5.24%).

10 Apr 2026 Sph Neutral

Ceasing to be a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.

9 Apr 2026 Sph Neutral

Becoming a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) became a substantial holder (5.3084%).

7 Apr 2026 Sph Neutral

Ceasing to be a substantial holder from CGF

CGF ceased to be a substantial holder.

2 Apr 2026 Sph Neutral

Ceasing to be a substantial holder

Citigroup Global Markets Australia Pty Limited (ACN 003 114 832) ceased to be a substantial holder.

Get real-time alerts for TLX

Receive AI-powered earnings summaries and instant notifications when Telix Pharmaceuticals Limited releases results.

Register Free